Drugs / Survivin-loaded dendritic cell injection
Survivin-loaded dendritic cell injection
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06524063 | Aug 2024 → Dec 2025 overdue | glioblastoma | Beijing Tricision Biotherapeutics Inc | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Survivin-loaded dendritic cell injection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06524063 ↗ |
| Modality | Cell therapy | “Targeted Survivin DC cell therapy” NCT06524063 ↗ |
| Route | Intravenous | “both intradermal (ID) and intravenous (IV) routes” NCT06524063 ↗ |